Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
IntroductionThe first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination. In this proof-of-c…